ライフサイエンスコーパス: atrial

1 T) catheter, pigs (n = 6) underwent discrete atrial ablation in a temperature control mode (60 degree

2 The areas of atrial abnormality were consistent among patients, most

3 The effects of the mutations on human atrial action potential and rate dependence were investi

4 ial myocytes and are responsible for shaping atrial action potentials.

5 his study was to assess whether an increased atrial adipose tissue mass posterior to the left atrium

6 sease), each gram increase of posterior left atrial adipose tissue was associated with 1.32 odds rati

7 ore likely in patients with complex surgical atrial anatomy (ie, Fontan palliation or atrial switch p

8 ine a family with dilated cardiomyopathy and atrial and ventricular arrhythmias.

9 Atrial and ventricular cardiac chambers behave as distin

10 VLDL modulates gap junctions and delays both atrial and ventricular conduction.

11 We associated Scn5a+/DeltaKPQ with increased atrial and ventricular fibrosis (both: p < 0.001).

12 covered distinct MEF2A co-regulators for the atrial and ventricular gene sets, and a subset of these

13 c conduction was associated with significant atrial and ventricular remodeling, along with systolic d

14 Transcriptomic analysis of atrial and ventricular tissue from adult MEF2A KO hearts

15 Left atrial appendage closure (LAAC) was approved by the U.S.

16 Over the past decade, percutaneous left atrial appendage closure has emerged as a valid alternat

17 l parameters of the left atrium and the left atrial appendage which have been shown to be associated

18 METHODS AND Human CPCs from the right atrial appendages from children of different ages underg

19 ate-dependent IKur-blocking effects on human atrial APs, and provide insights relevant to the potenti

20 RVESRI and right atrial area were strongly connected to the other right h

21 IART is the most common presenting atrial arrhythmia in patients with congenital heart dise

22 rial surface and 18 months of follow-up, the atrial arrhythmia recurrence rate was 15% after 1.4 +/-

23 ablation reinterventions in 13 patients for atrial arrhythmia, and cardioversions in 15 patients.

24 conduction disturbance and the occurrence of atrial arrhythmias and low left ventricular ejection fra

25 ein demonstrates increased susceptibility to atrial arrhythmias in mice where Notch has been transien

26 rders, but its applicability for terminating atrial arrhythmias remains largely unexplored.

27 d 82% (LPeAF) at 1 year and freedom from all atrial arrhythmias was 77% (PAF), 75% (PeAF), and 57% (L

28 tients admitted for dofetilide reloading for atrial arrhythmias were retrospectively reviewed.

29 y sought to assess the types and patterns of atrial arrhythmias, associated factors, and age-related

30 s to dynamic instabilities that may underlie atrial arrhythmias.

31 characteristics may serve as predictors for atrial arrhythmias.

32 s that may modify atrial conduction or treat atrial arrhythmias.

33 PMCA1(cko) hearts became more susceptible to atrial arrhythmic stress conditions than PMCA1(loxP/loxP

34 age arterial switch operations, but 20% were atrial baffling procedures (atrial switch operation) or

35 METHODS AND Neonatal rat atrial cardiomyocyte monolayers expressing a depolarizin

36 In addition, alterations of the atrial cardiomyocytes, increase of noncollagen deposits

37 They review evidence implicating atrial cardiomyopathy as an independent contributor to t

38 t drugs may prove to reduce stroke risk from atrial cardiomyopathy given its parallels to atrial fibr

39 Such an atrial cardiomyopathy may explain many cases of embolic

40 The term atrial cardiomyopathy, which has been used sporadically

41 ed source, including specifically those with atrial cardiomyopathy.

42 Our main finding is that when an atrial cell is paced under Ca overload conditions, Ca wa

43 6, which alters enhancer activity in a mouse atrial cell line and in embryonic zebrafish and differen

44 ular cells of the ventricles and only to few atrial cells (<5%) of the differentiated heart.

45 g point to explore the nonlinear dynamics of atrial cells and will yield insights into the trigger an

46 We argue further that this feature of atrial cells leads to dynamic instabilities that may und

47 rger proportion of dysregulated genes in the atrial chambers.

48 ifying new targets for drugs that may modify atrial conduction or treat atrial arrhythmias.

49 ng, genes encoding molecular determinants of atrial conduction velocity, including Scn5a (Nav1.5) and

50 s to understand how the processes regulating atrial contraction are remodelled during ageing and prov

51 ) weak-atriumm58 mutant (wea) with inhibited atrial contraction leading to a highly undeveloped ventr

52 ects of late systolic loading on ventricular-atrial coupling.

53 severe basal LVOTO (70-120 mm Hg), and left atrial dilatation (44-57 mm).

54 G) leads to spontaneous-onset AF preceded by atrial dilatation and conduction abnormalities.

55 ] per decade, 1.55; 95% CI, 1.11-2.15), left atrial dimension (HR per centimeter diameter, 1.43; 95%

56 Atrial dimensions and volumes were generally larger in m

57 The normal reference values of atrial dimensions, volumes, and empty fractions (EFs) we

58 disorders, infection, pollution, and cardiac atrial disorders independent of atrial fibrillation.

59 We propose a novel paradigm of atrial ECC that is based on tandem activation of the RyR

60 The P wave on an ECG is a measure of atrial electric function, and its characteristics may se

61 tment of AF, requires spatial information on atrial electrical excitation.

62 determine the effects of Notch signaling on atrial electrophysiology, we transiently activate Notch

63 itionally have been used as markers for left atrial enlargement, and both have been associated with i

64 Here, we found that adult human atrial epicardial cells were highly adipogenic through a

65 gnosis is associated with the development of atrial-esophageal fistula (AEF) and increased mortality.

66 MYBPHL was found to have high atrial expression with low ventricular expression.

67 he use of intracardiac electrograms to guide atrial fibrillation (AF) ablation has yielded conflictin

68 od pressure (BP) lowering prevents recurrent atrial fibrillation (AF) after catheter ablation in pati

69 itamin K antagonists (VKAs) in patients with atrial fibrillation (AF) and coexisting valvular heart d

70 Atrial fibrillation (AF) and left ventricular systolic d

71 Atrial fibrillation (AF) and stroke are important major

72 Both obesity and atrial fibrillation (AF) are increasing in epidemic prop

73 isease (CHD) are assumed to be vulnerable to atrial fibrillation (AF) as a result of residual shunts,

74 coronary artery evaluation in patients with atrial fibrillation (AF) by using invasive coronary angi

75 Recently published analysis of contemporary atrial fibrillation (AF) cohorts showed an association b

76 The long-term probability of developing atrial fibrillation (AF) considering genetic predisposit

77 rol is challenging in patients with extended atrial fibrillation (AF) duration and persistent/long-st

78 Atrial fibrillation (AF) has been reported as a strong i

79 Patients with heart failure (HF) and atrial fibrillation (AF) have higher circulating levels

80 uces dose-dependent termination of simulated atrial fibrillation (AF) in the absence of AF-induced el

81 Atrial fibrillation (AF) is a common arrhythmia.

82 Atrial fibrillation (AF) is a common cardiac disease in

83 Atrial fibrillation (AF) is common in heart failure (HF)

84 Atrial fibrillation (AF) is the most common cardiac arrh

85 Whether the pattern of atrial fibrillation (AF) modifies the risk/benefit of an

86 ated its role on prognosis in anticoagulated atrial fibrillation (AF) patients and determined whether

87 related to the quality of anticoagulation in atrial fibrillation (AF) patients, reflected by time in

88 and is the leading cause of mortality among atrial fibrillation (AF) patients.

89 rphology has been associated with drivers of atrial fibrillation (AF) risk, including left ventricula

90 kers interact with risk factors to influence atrial fibrillation (AF) risk.

91 and each manifestation of MetS is related to atrial fibrillation (AF) risks.

92 een increasing focus on the rising burden of atrial fibrillation (AF) since the turn of the millenniu

93 Atrial tachy-arrhytmias, such as atrial fibrillation (AF), are characterised by irregular

94 factor for thromboembolism in patients with atrial fibrillation (AF), but less is known about how di

95 Atrial fibrillation (AF), the most common sustained arrh

96 dial adipose tissue (EAT) is associated with atrial fibrillation (AF), the most frequent cardiac arrh

97 monstrated conflicting mechanisms underlying atrial fibrillation (AF), with the spatial resolution of

98 tributors to the self-perpetuating nature of atrial fibrillation (AF).

99 els constitute a new target for treatment of atrial fibrillation (AF).

100 Accumulating evidence links inflammation and atrial fibrillation (AF).

101 id valve (TV) may occur secondary to chronic atrial fibrillation (AF).

102 c cardiovascular disease (ASCVD) events, and atrial fibrillation (AFib) in a multiethnic cohort.

103 rteen patients with long-standing persistent atrial fibrillation (duration, 12-72 months) underwent p

104 preexcitation had higher adjusted hazards of atrial fibrillation (hazard ratio [HR], 3.12; 95% confid

105 ibrillation (PeAF), long-standing persistent atrial fibrillation (LPeAF), or paroxysmal atrial fibril

106 Among 91330 patients with nonvalvular atrial fibrillation (mean age, 74.7 years [SD, 10.8]; me

107 d substantially outside the South, including atrial fibrillation (Northwest), aortic aneurysm (Midwes

108 nucleotide polymorphisms was associated with atrial fibrillation (odds ratio=0.89 per SD change; 95%

109 t atrial fibrillation (LPeAF), or paroxysmal atrial fibrillation (PAF); if right atrial sites are imp

110 -world" patients if sources drive persistent atrial fibrillation (PeAF), long-standing persistent atr

111 tial prevalence of asymptomatic, subclinical atrial fibrillation (SCAF) in patients with pacemakers a

112 liable prediction of very late recurrence of atrial fibrillation (VLRAF) occuring >12 months after ca

113 ice of Dosing With Warfarin in Patients With Atrial Fibrillation [ENGAGE AF-TIMI 48]; NCT00781391).

114 METHODS AND Patients undergoing first atrial fibrillation ablation and postinterventional esop

115 AEF has been reported with all modalities of atrial fibrillation ablation despite esophageal temperat

116 es, are there nevertheless data that support atrial fibrillation ablation in asymptomatic patients?

117 AEF complicating atrial fibrillation ablation is associated with a high m

118 DS AND We prospectively studied 33 AT (post- atrial fibrillation ablation or surgical mitral valve re

119 ion ablation that occurs in 0.1% to 0.25% of atrial fibrillation ablation procedures.

120 eal perforation is a dreaded complication of atrial fibrillation ablation that occurs in 0.1% to 0.25

121 Since the original description of atrial fibrillation ablation, numerous studies have demo

122 ection (PVR) still determines recurrences of atrial fibrillation after contact force (CF)-guided pulm

123 dies (GWAS) included 17,931 individuals with atrial fibrillation and 115,142 referents; the exome-wid

124 In this Danish cohort study of patients with atrial fibrillation and a single stroke risk factor, the

125 Patients were included who had atrial fibrillation and an indication for oral anticoagu

126 ibutor to the risk of stroke associated with atrial fibrillation and as a determinant of arrhythmia p

127 with VKAs to treat patients with nonvalvular atrial fibrillation and concomitant aspirin therapy.

128 s in preventing recurrences of nonparoxysmal atrial fibrillation and reducing hospital admissions.

129 eter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction [CAMERA-MRI

130 We identified determinants of new-onset atrial fibrillation and, using propensity matching, char

131 Epicardial breakthrough waves (EBW) during atrial fibrillation are important elements of the arrhyt

132 outpatient clinics if they had no history of atrial fibrillation but had any of the following: CHA2DS

133 ssumptions of this simulation, patients with atrial fibrillation can be triaged to an optimal warfari

134 association study (GWAS) that included 8,180 atrial fibrillation cases and 28,612 controls with follo

135 an provides stroke prevention in nonvalvular atrial fibrillation comparable to warfarin, with additio

136 tes, patients with diabetes also had a lower Atrial Fibrillation Effects on Quality of Life score of

137 pared with warfarin therapy in patients with atrial fibrillation from the perspective of the US healt

138 Radiofrequency catheter ablation for atrial fibrillation has become an important therapy for

139 the incidence, risk factors, and outcomes of atrial fibrillation in a cohort of critically ill patien

140 derlie the development of conditions such as atrial fibrillation in humans.

141 The excess risk of atrial fibrillation in individuals with type 1 diabetes

142 t ventricular pacing (RVP) increases risk of atrial fibrillation in patients with implantable cardiov

143 x new loci were specifically associated with atrial fibrillation in the Japanese population after com

144 To investigate genetic loci associated with atrial fibrillation in the Japanese population, we perfo

145 Over a third of patients with atrial fibrillation in this large outpatient registry re

146 Atrial fibrillation increased with age to surpass IART a

147 Adults with atrial fibrillation initiating dabigatran or warfarin th

148 Atrial fibrillation is also a common complication and is

149 Catheter ablation of atrial fibrillation is associated with a risk of cerebra

150 sient and frequently unrecognized, new-onset atrial fibrillation is associated with poor hospital out

151 coronary artery disease, heart failure, and atrial fibrillation is discussed in detail.

152 ticoagulants among patients with nonvalvular atrial fibrillation is not known.

153 Atrial fibrillation is one of the major cardiovascular h

154 12-lead electrocardiogram without pacing or atrial fibrillation noted on their baseline Jackson Hear

155 s repeatedly emphasized as a risk factor for atrial fibrillation or flutter (AF).

156 We observed six cases of self-terminating atrial fibrillation or flutter and six cases of partial

157 0- and 360-day complications, and shocks for atrial fibrillation or supraventricular tachycardia.

158 uring atrial fibrillation, thereby promoting atrial fibrillation persistence.

159 therapy for ARISTOTLE-eligible patients with atrial fibrillation provides clinical benefits at an inc

160 se maps presented reentrant activity just in atrial fibrillation recordings accounting for approximat

161 Once diagnosed, atrial fibrillation requires chronic, multidimensional m

162 e of the PR interval comprises modulators of atrial fibrillation risk and obesity.

163 KCND3 and NEBL genes, which are relevant to atrial fibrillation susceptibility.

164 A total of 1585 patients with atrial fibrillation undergoing PVI from the Swedish Cath

165 omatic paroxysmal (n=345; 42%) or persistent atrial fibrillation underwent postprocedural esophageal

166 We found atrial fibrillation using automated detection (>/= 90 s

167 sted regression analyses, clinical new-onset atrial fibrillation was associated with increased hospit

168 Most atrial fibrillation was paroxysmal; less than 2% of admi

169 New-onset atrial fibrillation was subclinical or went undocumented

170 ND Characteristics from 14 206 patients with atrial fibrillation were integrated into a validated war

171 nd including 91330 patients with nonvalvular atrial fibrillation who received at least 1 NOAC prescri

172 atched cohorts of patients with non-valvular atrial fibrillation with incident exposure to dabigatran

173 To determine the association of new-onset atrial fibrillation with outcomes, including ICU length

174 ing the probability of a first occurrence of atrial fibrillation within the following 24 hours, we pe

175 Atrial fibrillation would have gone undetected in most p

176 One serious adverse event (transient atrial fibrillation) occurred in 205 subjects who underw

177 es Registry for Better Informed Treatment of Atrial Fibrillation) registry, a prospective, nationwide

178 f thromboembolic events-European Registry in Atrial Fibrillation).

179 (23.8%) with heart failure, 109 (9.2%) with atrial fibrillation, 89 (8%) with myocardial infarction,

180 independent risk factor for both stroke and atrial fibrillation, and in the setting of AF, type 2 di

181 diomyopathy, cardiac conduction disturbance, atrial fibrillation, and malignant ventricular arrhythmi

182 provide insights into the molecular basis of atrial fibrillation, and may facilitate the identificati

183 tly because of age but also stroke severity, atrial fibrillation, and prestroke functional limitation

184 ed with higher rates of acute kidney injury, atrial fibrillation, and transfusion requirements, where

185 Cspg4 locus led to ventricular arrhythmias, atrial fibrillation, atrioventricular conduction defects

186 risk of short-term mortality, renal failure, atrial fibrillation, bleeding, and length of intensive c

187 r rates of stroke than warfarin in trials of atrial fibrillation, but large-scale evaluations in clin

188 pathology consultation, anticoagulation for atrial fibrillation, discharge on statin, lipid manageme

189 This issue provides a clinical overview of atrial fibrillation, focusing on diagnosis, treatment, a

190 ariants of CAD were linked to development of atrial fibrillation, heart failure, and death.

191 Early diagnosis of atrial fibrillation, ideally before the first complicati

192 ily history of sudden death (FHSD), syncope, atrial fibrillation, non-sustained ventricular tachycard

193 double the number of known genetic loci for atrial fibrillation, provide insights into the molecular

194 patients >/=18 years of age with nonvalvular atrial fibrillation, randomized to either VKAs or NOACs,

195 ction mutations that cause a genetic form of atrial fibrillation, S140G and V141M, drastically slow I

196 infarction, new or worsening heart failure, atrial fibrillation, stroke, deep venous thrombosis, car

197 ich may enhance the occurrence of EBW during atrial fibrillation, thereby promoting atrial fibrillati

198 To further define the genetic basis of atrial fibrillation, we performed large-scale, trans-anc

199 no difference was observed in terms of free atrial fibrillation-recurrence rates: 79.4% in control v

200 s warranted for stroke prevention during non-atrial fibrillation-related cardiac surgery.

201 oagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarctio

202 ith higher rates of device complications and atrial fibrillation.

203 tion is indicated after the first episode of atrial fibrillation.

204 myocardial infarction, non-fatal stroke, or atrial fibrillation.

205 have been associated with increased risk of atrial fibrillation.

206 nsion, thromboembolism, QT prolongation, and atrial fibrillation.

207 patients with both paroxysmal and persistent atrial fibrillation.

208 l; less than 2% of admissions were always in atrial fibrillation.

209 chial index were among the top predictors of atrial fibrillation.

210 new-onset if there was no prior diagnosis of atrial fibrillation.

211 tors and specific stroke mechanisms, such as atrial fibrillation.

212 ing VKAs and NOACs (n=71 681) in nonvalvular atrial fibrillation.

213 nting thromboembolic events in patients with atrial fibrillation.

214 ure was associated with an increased risk of atrial fibrillation.

215 trial thromboembolism even in the absence of atrial fibrillation.

216 hese chronic treatments to all patients with atrial fibrillation.

217 and cardiac atrial disorders independent of atrial fibrillation.

218 revention around the world for patients with atrial fibrillation.

219 insights into the trigger and maintenance of atrial fibrillation.

220 of stroke/systemic embolism in patients with atrial fibrillation.

221 ve to warfarin for patients with nonvalvular atrial fibrillation.

222 atrial cardiomyopathy given its parallels to atrial fibrillation.

223 vascular disease, stroke, heart failure, and atrial fibrillation.

224 limitations, stroke severity, and history of atrial fibrillation.

225 with a history of ischemic heart disease or atrial fibrillation.

226 g can be used to evaluate characteristics of atrial fibrosis.

227 ptomatic recurrence of AF/atrial tachycardia/atrial flutter lasting >30 seconds, determined 3 months

228 pothesized that VLDL can modulate and reduce atrial gap junctions.

229 ular (LV) dysfunction, ischemic MR, and left atrial infarction (LAI); and 2) to analyze how LA remode

230 s a critical autoantigen in the mediation of atrial inflammation in mice and that our model may be he

231 epitope, SERCA2a 971-990, induces widespread atrial inflammation without affecting noncardiac tissues

232 ilic myocarditis with severe ventricular and atrial inflammation, which progressed to severe DCMi.

233 whether Notch reactivation may stably alter atrial ion channel gene expression and arrhythmia induci

234 Although left atrial (LA) dysfunction is common in heart failure with

235 Purpose To determine whether left atrial (LA) strain quantification with cardiac magnetic

236 smurality was correctly identified in 87% of atrial lesions.

237 Overall, women demonstrated higher peak atrial longitudinal systolic strain (39.34+/-7.99% versu

238 nd showed age-dependent more pronounced peak atrial longitudinal systolic strain functional decay tha

239 oach to induce and locally target a rotor in atrial monolayers.

240 Samples of human left atrial myocardium showed a positive correlation between

241 channels (SK, KCa 2) are expressed in human atrial myocytes and are responsible for shaping atrial a

242 ABSTRACT: In atrial myocytes Ca(2+) release during excitation-contrac

243 regular-type action potentials of PMCA1(cko) atrial myocytes increased significantly under Ca(2+) ove

244 -SR ([Ca(2+) ]SR ; fluo-5N) Ca(2+) in rabbit atrial myocytes revealed that Ca(2+) release from j-SR r

245 ol was significantly prolonged in PMCA1(cko) atrial myocytes under basal conditions, with Ca(2+) over

246 regulation controlling the repolarization of atrial myocytes.

247 shown that SR Ca content is increased in old atrial myocytes.

248 ulate the reduced fat oxidation and elevated atrial natriuretic peptide message of cardiac hypertroph

249 for reduced fat oxidation to affect cardiac atrial natriuretic peptide, and thus, induce adipose lip

250 The cardiac natriuretic peptides (NPs), atrial NP and B-type NP, regulate fluid homeostasis and

251 Most atrial parameters correlated with age.

252 histopathology, atrial-specific physiology, atrial pathology, impact on arrhythmia occurrence, imagi

253 Intraoperatively a small infected left atrial perforation was oversewn and a fistula to the rig

254 ationship between the esophagus and the left atrial posterior wall is variable, and the esophagus is

255 ic variables such as cardiac index and right atrial pressure have consistently been associated with s

256 his study provides mechanistic insights into atrial proarrhythmia with SQT3 Kir2.1 mutations and high

257 function on echocardiography, ratio of right atrial/pulmonary capillary wedge pressure, hemoglobin) w

258 become a broadly used technique to identify atrial reentrant circuits for ablative therapy guidance.

259 nakalant and AP14145 significantly prolonged atrial refractoriness and reduced AF duration without af

260 is associated with structural and functional atrial remodeling and increased incidence of extra-PV tr

261 s of the gene program linked to CREM-induced atrial remodeling were identified in the expression of g

262 SK currents play a role in porcine atrial repolarization, and pharmacological inhibition of

263 associated with gene expression in 329 left atrial samples.

264 progressive valvulopathy, hypertension, and atrial scars from previous heart surgery.

265 The adipogenic property of the atrial secretome was enhanced in AF patients.

266 ed patients immediately prior to an elective atrial septal defect repair procedure.

267 Closure of atrial septal defect with the AMPLATZER Septal Occluder

268 g patients, most commonly involving the left atrial septum (32/43; 74.4%).

269 roxysmal atrial fibrillation (PAF); if right atrial sites are important; and what the long-term succe

270 sue Doppler imaging [TDI] e', E/e', and left atrial size) with concomitant N-terminal pro-brain natri

271 ain arrhythmic SAN pacemaker activity in the atrial-specific Na(+) /Ca(2+) exchange (NCX) knockout (K

272 d aspects of the definition, histopathology, atrial-specific physiology, atrial pathology, impact on

273 identified numerous factors that modify the atrial substrate and increase AF susceptibility.

274 known that AF genesis requires a vulnerable atrial substrate and that the formation and composition

275 rth, increasing appreciation of thrombogenic atrial substrate and the common coexistence of cardiac a

276 rging evidence indicates that a thrombogenic atrial substrate can lead to atrial thromboembolism even

277 After ablation of 17 +/- 10% of the left atrial surface and 18 months of follow-up, the atrial ar

278 ns, but 20% were atrial baffling procedures (atrial switch operation) or 2-stage repairs (pulmonary a

279 cal atrial anatomy (ie, Fontan palliation or atrial switch procedure).

280 Atrial tachy-arrhytmias, such as atrial fibrillation (AF

281 become the treatment strategy of choice for atrial tachyarrhythmias in patients with congenital hear

282 Atrial tachyarrhythmias recurred in 28 PVI-only group pa

283 hundred and forty-four patients with CHD and atrial tachyarrhythmias undergoing radiofrequency cathet

284 ilure (3%), liver abscesses (3%), paroxysmal atrial tachycardia (3%), thoracic pain (3%), upper gastr

285 Here, we assess the efficacy of optogenetic atrial tachycardia (AT) termination in human hearts usin

286 Acute procedural success of atrial tachycardia ablation in congenital heart patients

287 ary outcome was symptomatic recurrence of AF/atrial tachycardia/atrial flutter lasting >30 seconds, d

288 nd this drove 30% (7/23) of our postablation atrial tachycardias.

289 r blood pressure in pigs subjected to 7 days atrial tachypacing, as well as in sham-operated control

290 a thrombogenic atrial substrate can lead to atrial thromboembolism even in the absence of atrial fib

291 (2+) homeostasis and electrical stability in atrial tissue has been investigated at both organ and ce

292 In this study, human atrial tissues from the patients with rheumatic mitral v

293 cification, early transmitral velocity/late (atrial) transmitral velocity (E/A) ratio, global longitu

294 et al. (2017) report prospective markers of atrial versus ventricular myocyte formation from hPSCs a

295 However, the mechanisms that direct atrial versus ventricular specification remain largely u

296 ar global longitudinal strain (GLS) and left atrial volume index (LAVI) have been recently proposed a

297 diastolic dysfunction (E/e') and 5 with left atrial volume index.

298 a was more closely correlated with the right atrial volume than right ventricular end-systolic volume

299 exed left ventricular mass, and indexed left atrial volume.

300 36 ml to 122 +/- 30 ml; p < 0.001) and left atrial volumes (106 +/- 36 ml to 69 +/- 24 ml; p < 0.001